Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym
Recruiting · NCT06760156 · Registry updated 2026-04-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tafasitamab and Lenalidomide as First Salvage Therapy for Residual Large B Cell Lym | large B-cell lymphoma | Recruiting | Phase 2 | 2026-04-03 | NCT06760156 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
| Incyte Corporation | 153 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |